Almost three decades ago, a brilliant viewpoint has suggested that a dysregulated immunological switch in favor of Th2 type responses over the Th1 type response is associated with progression of HIV to AIDS and this switch was characterized by loss of the protective antiviral IL-2- and IFN-γ production; furthermore, those expert researchers have suggested that thousands of seronegative, HIV-exposed (many on multiple occasions) individuals have generated strong Th1 dependent IL-2 responses to HIV antigens [1]. Interestingly, a similar imbalance in Th1/Th2 types with a Th2 favorable switch or failure in the activation of Th1 and reduced IFN-γ production was observed in deceased SARS patients or critically ill MERS patients, whereas a Th1 strong response, which is pivotal in mediating virus-specific adaptive immunity, was observed in mild patients [2].

Importantly, CD4 + and CD8 + T cell cytokines were significantly diminished in COVID-19 patients as compared to healthy controls, and subverted T cell composition and/or homeostasis were also suggested to share in COVID-19 pathogenesis, and IL-6 was implied to induce this immunopathological process in patients suffering from severe or critical COVID-19 [2, 3]. As an explanation, SARS CoV-2 was suggested to dysregulate the antiviral immune response at an early stage leading to number depletion and functional exhaustion of NK and CD8 + T cells which were restored in those who survived, and a recommendation to improve the immune response at the early stage of SARS CoV-2 infection was concluded [4].

However, though a variable immunological response was suggested to predict mortality in COVID-19 patients and Th2, Th17 cell, and Treg percentages were significantly lower in deceased COVID-19 cases than recovered and healthy control [5], yet COVID-19’s high morbidity and mortality were still suggested to be related to low Th1 immunity [6], and spike-specific Th1 cells capable of IL7-dependent homeostatic proliferation were shown to predict survival from severe COVID-19 [7]. Similarly, un-sustained effective Th1 response and dominant Th2 response were demonstrated, in a prospective cohort of patients, to be related to a worse COVID-19 prognosis [8], and we suggest that their observed higher levels of IFN-γ related to mortality might be, similar to other types of interferons, induced in critically ill patients in a final futile attempt to tune the untuned antiviral immunity [9] that exacerbate, instead of ameliorate, the induced immunopathic damage [10], and we would like to emphasize defective interferon response as a major culprit responsible for COVID-19 deterioration [11, 12].

In another explanation to the various clinical outcomes, ACE2 was suggested to regulate the immune response in SARS and SARS CoV-2 including activation of B cells, macrophages, Th1 cells and the inhibition of Treg cells and CD8 + T cells[13] and ACE2 [14] and other discovered [15] and potentially yet to be discovered genetic polymorphisms e.g. CARD 14 [16] might be reflected through different T cell virus specific and other immunological responses. Thus, while some SARS CoV-2 exposed patients would remain symptoms-free, including asymptomatic seronegative COVID-19 patients [17], others suffer from mild-moderate or severe COVID-19. Similarly, some COVID-19 patients will recover smoothly, while others complain of COVID-19 associated autoimmune complications [18] which are hypothesized to be due to transient immunosuppression of the innate and acquired immunity [19].

Thus, we have suggested a new terminology for SARS CoV-2 induced dysregulated immune response, monocytic dysrhythmia [11], to be noted that an imbalanced immune-inflammatory response was previously described to drive the development of COVID-19 [20]. Meanwhile, we preferred the term dysrhythmia over dysregulation as we postulate that tuning the immune response deserves more research work that might lead to novel highly needed immunotherapeutic drugs.

Notably, we suggested to name para COVID syndrome [21] preferring it to post COVID to embrace a potential that SARS CoV-2 might induce immune-mediated disorders whether before or after recovery as well as it might persist latent, for yet unspecified period, in some cells and tissues [22] to induce, at least some of, what is currently being described of several post COVID-19 diseases affecting the nervous system [23, 24]. Para COVID might also describe immunological reactivation of various types of herpes viruses which are described in critically ill COVID-19 patients [25], and we recommend further investigations to assess potential SARS CoV-2 direct latency or indirect persistent functional dysrhythmia, respectively, in some immune cells such as the migrating interstitial macrophages [26, 27]. Obviously, SARS CoV-2 is known to possess several adaptive and immune evasive differences from other coronaviruses, and our knowledge about RNA viruses and their capabilities to remain latent for long duration is still evolving; thus, SARS CoV-2 potential latency might eventually resemble the newly described latent Ebola virus (https://www.sciencemag.org/news/2021/03/new-ebola-outbreak-likely-sparked-person-infected-5-years-ago).

In the same manner, a fourth RNA virus induced fatal disease; Ebola virus disease might also be considered to possess a similar n-AIDS potential as regards to its induced dysregulation of the immune system [28], its long lasting T and B cell immunological dysfunction which was further described in Ebola survivors [29], as well as the dysregulated inflammatory and immunological immune response in both Ebola virus disease survivor and deceased cases [30]. Additionally, a fifth RNA virus with a high fatality rate; Nipah virus might be similarly reclassified as it has been shown to manipulate the inflammatory and immunological response including the interferon homeostasis [31]. Nipah virus infection was also shown to influence the pro-inflammatory and leucocyte attracting cytokines in a manner that determines the disease course [32] and to induce a dysregulated immune recruitment that led to acute vasculitis among other several induced immune dysregulatory mechanisms [33].

Taken together, we postulate that abnormal cytokine and chemokine, known and yet to be discovered, dependent lymphocyte distraction (clinically manifested by lymphopenia) into the lungs (causing ARDS) or away from the lungs to other organs (causing multiple inflammatory syndrome) might reason for COVID-19 pathogenesis and complications [34]. Moreover, we suggest that SARS, MERS, and SARS CoV-2, the three virulent RNA corona viruses which emerged in the past two decades, which are also anticipated to be joined by other potentially fatal similar viruses, together with Ebola virus disease and Nipah virus infection might be considered for a novel immunopathological reclassification, n-AIDS. We wish by introducing a novel academic classification (n-AIDS) and modifying an existing preliminary one (para COVID) to encourage academic and clinical researchers to evolve the topic further to be ready for the anticipated similar viruses/pandemics in the coming years and to avoid any unnecessary delay that might cause terminology pollution. n-AIDS acknowledges the potential immune-linked pathogenesis of those viruses that might induce their complications and/or fatalities as shown by their peculiar immune monocytic, Th1/Th2, and potentially other immune cells dysrhythmia that though seems hyperactive, it is practically deficient/incompetent. We also encourage further investigations to assess potential SARS CoV-2 latency in some survivors, as recently shown for Ebola, to fully explore para COVID syndrome.

Interestingly, though the three potentially fatal coronaviruses share some similarities with HIV [35], and that other potential similarities between SARS CoV-2 and Nipah virus have been also described [36], these viruses and Ebola virus also differ from HIV in several important aspects including their specific immunological targets and their main tendency for acute progressive onset and complications, and hence n-AIDS is suggested to be more scientifically accurate to classify them.

Accordingly, we suggest that our suggested novel classification of acute immune-dysrhythmic syndrome might properly guide us in our quest for a potential cure; as it is only when we know the cause, we can insightfully figure out the therapy, and we recommend to focus on immune-modulation as a potential effective COVID-19 therapy [6, 11, 37], Ebola virus disease [38], and Nipah virus infection [31]. Moreover, we hypothesize that our evolved real-life immunomodulatory COVID-19 management protocol [11, 37] that guided us, through its remarkable clinical efficacy against COVID-19, to this hypothesis might also prove beneficial when tested in clinical trials for early management of the mentioned and other RNA viruses that would be classified to cause n-AIDS as well as to potentially manage other diseases caused by altered Th1/Th2 balance.

Finally, I agree with an expert who said: “I think there is just so much going on here, and we are just putting our foot the river. I’ll just leave you with this thought: we are closer to the beginning than the end of this” (https://www.healio.com/news/rheumatology/20210416/data-supports-covid19-as-autoimmunity-trigger-in-patients-without-preexisting-imids).